Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.

Comparative Effects of Direct Renin Inhibitor and Angiotensin Receptor Blocker on Albuminuria in Hypertensive Patients with Type 2 Diabetes. A Randomized Controlled Trial

Open access

Abstract

BACKGROUND: In patients with diabetes, albuminuria is a risk marker of end-stage renal disease and cardiovascular events. An increased renin-angiotensin system activity has been reported to play an important role in the pathological processes in these conditions. We compared the effect of aliskiren, a direct renin inhibitor (DRI), with that of angiotensin receptor blockers (ARBs) on albuminuria and urinary excretion of angiotensinogen, a marker of intrarenal renin-angiotensin system activity. METHODS: We randomly assigned 237 type 2 diabetic patients with high-normal albuminuria (10 to <30 mg/g of albumin-to-creatinine ratio) or microalbuminuria (30 to <300 mg/g) to the DRI group or ARB group (any ARB) with a target blood pressure of <130/80 mmHg. The primary endpoint was a reduction in albuminuria. RESULTS: Twelve patients dropped out during the observation period, and a total of 225 patients were analyzed. During the study period, the systolic and diastolic blood pressures were not different between the groups. The changes in the urinary albumin-to-creatinine ratio from baseline to the end of the treatment period in the DRI and ARB groups were similar (-5.5% and -6.7%, respectively). In contrast, a significant reduction in the urinary excretion of angiotensinogen was observed in the ARB group but not in the DRI group. In the subgroup analysis, a significant reduction in the albuminuria was observed in the ARB group but not in the DRI group among high-normal albuminuria patients. CONCLUSION: DRI and ARB reduced albuminuria in hypertensive patients with type 2 diabetes. In addition, ARB, but not DRI, reduced albuminuria even in patients with normal albuminuria. DRI is not superior to ARB in the reduction of urinary excretion of albumin and angiotensinogen.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0164936

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig 1 Study subject disposition.
Fig 1 Study subject disposition.CC BY · PubMed Central
Fig 2 The mean changes in the systolic blood pressure and diastolic blood pressure during follow-up for the two treatment arms (A) and for the subgroups (B). DRI; direct renin inhibitor, ARB; angiotensin receptor blocker, HNA; high normal albuminuria, MA; microalbuminuria. Error bars represent 95% confidential intervals.
Fig 2 The mean changes in the systolic blood pressure and diastolic blood pressure during follow-up for the two treatment arms (A) and for the subgroups (B). DRI; direct renin inhibitor, ARB; angiotensin receptor blocker, HNA; high normal albuminuria, MA; microalbuminuria. Error bars represent 95% confidential intervals.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 24 references

Cited by

See all 18

Metadata

Authors
Uzu, T., Araki, S.-I., Kashiwagi, A., Haneda, M., Koya, D., Yokoyama, H., Kida, Y., Ikebuchi, M., Nakamura, T., Nishimura, M., Takahara, N., Obata, T., Omichi, N., Sakamoto, K., Shingu, R., Taki, H., Nagai, Y., Tokuda, H., Kitada, M., Misawa, M., Nishiyama, A., Kobori, H., Maegawa, H., & The Shiga Committee for Preventing Diabetic Nephropathy
Affiliations
  • Shiga University of Medical Science (JP)
  • Kusatsu General Hospital (JP)
  • Asahikawa Medical University (JP)
  • Kanazawa Medical University (JP)
  • Omihachiman Community Medical Center (JP)
  • Nagahama City Hospital (JP)
  • AKO City Hospital (JP)
  • Osaka National Hospital (JP)
  • St. Marianna University School of Medicine (JP)
  • Nagahama Red Cross Hospital (JP)
  • Kagawa University (JP)
Corresponding author
Uzu, Takashi
Venue
PLOS ONE
Published
2016-12-29
Volume
11
Issue
12
Pages
e0164936
ISSN
1932-6203 (ISSN-L)
OpenAlex
W2563595666
Cited by
18
References
24
Citations by year
2026: 1 · 2025: 2 · 2024: 2 · 2023: 1 · 2022: 2 · 2020: 2 · 2019: 4 · 2018: 3 · 2017: 1
FWCI
2.68
Type
journal article
Language
en
Open access
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Figshare (submittedVersion, cc-by)
Funders
Japan Diabetes Foundation
Topics
  • Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
Keywords
aliskiren, renin inhibitors, angiotensin receptor blockers, albuminuria, type 2 diabetes, hypertension, angiotensinogen, intrarenal renin-angiotensin system, microalbuminuria, renin-angiotensin system, albumin-creatinine ratio
MeSH terms
Renin Inhibitors, Albuminuria, Amides, Angiotensinogen, Antihypertensive Agents, Blood Pressure, Creatinine, Diabetes Mellitus, Type 2, Diabetic Nephropathies, Fumarates, Humans, Hypertension, Kidney Failure, Chronic, Prospective Studies, Renin-Angiotensin System, Treatment Outcome, Angiotensin Receptor Antagonists

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Comparative Effects of Direct Renin Inhibitor and Angiotensin Receptor Blocker on Albuminuria in Hypertensive Patients with Type 2 Diabetes. A Randomized Controlled Trial. https://app.cochat.ai/papers/10.1371/journal.pone.0164936
The paper
Uzu, T., Araki, S.-I., Kashiwagi, A., Haneda, M., Koya, D., Yokoyama, H., Kida, Y., Ikebuchi, M., Nakamura, T., Nishimura, M., Takahara, N., Obata, T., Omichi, N., Sakamoto, K., Shingu, R., Taki, H., Nagai, Y., Tokuda, H., Kitada, M., . . . The Shiga Committee for Preventing Diabetic Nephropathy. (2016). Comparative Effects of Direct Renin Inhibitor and Angiotensin Receptor Blocker on Albuminuria in Hypertensive Patients with Type 2 Diabetes. A Randomized Controlled Trial. PLOS ONE. https://doi.org/10.1371/journal.pone.0164936

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.